Invivyd Inc. Announces Proposed Public Offering of Common Stock

Invivyd, Inc. (Nasdaq: IVVD), a biotechnology company specializing in the development of next-generation candidate antibodies for COVID-19 prevention and treatment, has announced a proposed underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price. Cantor is set to serve as the sole book-running manager for this offering.

The proceeds from this public offering are intended to fund multiple initiatives, including the VYD2311 clinical program and the research and development of pipeline projects. This strategic move aims to bolster Invivyd’s efforts in advancing its COVID-19 treatment solutions, particularly focusing on the development of its molecules, NVD200, and other promising candidates.

Financial Overview and Recent Performance

As of August 18, 2025, Invivyd’s stock closed at $0.571, reflecting a significant decline from its 52-week high of $2.74 on February 5, 2025. The stock’s 52-week low was recorded at $0.355 on January 30, 2025. Despite the recent downturn, the company has maintained a focus on its core mission of developing effective COVID-19 treatments.

In its Q2 2025 financial report, Invivyd reported revenue growth, although it missed its profitability target. This mixed financial performance underscores the challenges the company faces in balancing growth with profitability.

Ongoing Research and Development

Invivyd has continued to demonstrate the efficacy of its key products, PEMGARDA (pemivibart) and VYD2311, against the currently dominant SARS-CoV-2 variant XFG, also known as “Stratus.” Recent in vitro neutralization data have shown consistent and potent neutralizing activity against this variant, which is driving a growing wave of COVID-19 cases in the United States.

The company’s ongoing research efforts are supported by positive data from the Centers for Disease Control and wastewater surveillance, indicating the relevance and urgency of its work in combating the evolving pandemic.

Market and Analyst Perspectives

Analysts have maintained a positive outlook on Invivyd’s prospects. H.C. Wainwright has continued to rate Invivyd stock as a “Buy,” citing the company’s progress on the VYD2311 path. This endorsement reflects confidence in Invivyd’s strategic direction and its potential to deliver impactful COVID-19 solutions.

In summary, Invivyd’s proposed public offering represents a critical step in securing the necessary funding to advance its clinical programs and pipeline development. With continued research success and supportive analyst ratings, Invivyd is poised to play a significant role in the ongoing fight against COVID-19.